WACKER and EVANIUM partner to commercialize CAVABERINE berberine ingredient

Deal and roles

WACKER and EVANIUM formed an exclusive distribution partnership to bring EVANIUM’s berberine ingredient to market under the name CAVABERINE® powered by OPTISOLV®. WACKER contributes global distribution, regulatory infrastructure, and cyclodextrin market expertise, while EVANIUM provides the OPTISOLV® delivery technology and the developed ingredient.

Technology and benefits

Berberine is poorly soluble and poorly absorbed, leading conventional products to require daily doses of 1,000–1,500 mg and causing gastrointestinal discomfort and compliance issues. OPTISOLV® uses a dual‑coating approach—an inner cyclodextrin‑based core and an outer phospholipid shell—to stabilize berberine in a crystal‑free state and enhance absorption, enabling more efficient delivery at lower doses.

Market, recognition and launch

Demand for berberine has risen rapidly as metabolic health entered the mainstream, with global berberine supplement launches growing at a 58% compound annual rate from 2021 to 2025. The ingredient received the Most Innovative Nutraceutical Ingredient award at Vitafoods Europe Startup Challenge 2026. WACKER will present CAVABERINE® in North America at SupplySide Global in Las Vegas on October 28, targeting the US market first; the global weight‑loss supplement market is estimated at $35.8 billion in 2026.

Commercial rationale

The partnership is positioned as open innovation to accelerate market access: EVANIUM developed and scaled the technology to industrial production, and WACKER provides the commercial reach to put the finished ingredient in front of customers worldwide, shortening time to market for both parties and end users.